FPI Stock Recent News

DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (the “Company”) today announced it will release its financial results for the fourth quarter and year ended December 31, 2024, after 5 p.m. (Eastern Time) on Wednesday, February 19, 2025, and will host a conference call the following day, Thursday, February 20, 2025, at 11:00 a.m. (Eastern Time) to discuss the financial results and provide a company update. The call can be accessed live over the phone by dialing 1-800-715-9871 and usin.

Warren Buffett once offered sage advice on how to pick winning stocks. We have identified some of these types of stocks trading at compelling bargains. We share several high-conviction picks in this article.

Land has proven to be an excellent long-term risk-adjusted investment. Fortunately, there are numerous opportunities to buy it at a steep discount right now. I share three compelling opportunities, yielding up to 7.3% with big buybacks involved as well.

DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (the “Company” or “FPI”) today announced the tax treatment of our 2024 common stock distributions, as summarized in the following table. Farmland Partners Inc. CUSIP: 31154R109 EIN: 46-3769850 Farmland Partners Inc. 2024 Dividend Treatment   Common Stock   Dividends Capital Gains DeclarationDate Payment Date Record Date DistributionPer Share DistributionPer Share Allocable to2024 TaxableOrdinary(Box 1a) Qualified (Box 1b)(1) Total(Box.

The REIT sector took a beating in December with an average total return of -6.85% but still finished in the black for full year 2024 (+3.70%). Small cap (-5.98%) and mid cap REITs (-6.62%) outperformed large caps (-7.43%) and micro caps (-8.63%) in December. Only 9.68% of REIT securities had a positive total return in December. 55.63% had a positive total return for all of 2024.

Data suggests that Farmland Partners Inc. offers diversification benefits with a weak correlation to major equity and real estate ETFs. The REIT's business model includes leasing agricultural land, selling crops, and providing ancillary services, ensuring revenue diversification. Strong fundamentals, including high collection rates, long-term leases, and involvement in renewable energy, support a positive outlook for 2025.

Farmland Partners executed two significant transactions in Q4 2024 producing proceeds of $308 million and exiting the Florida, South and North Carolina farmland markets. The transaction increases the significance of California permanent crop farms which are more difficult to value. I estimate FPI's AFFO should increase to $0.35-$0.40/share in 2025 driven by deleveraging and cost savings. Even so, the AFFO multiple remains too high.

Avoid private equity and REITs offering unsustainable high yields; they often rely on risky investments or leverage, leading to potential capital destruction. We prefer to look at the cashflows first to ensure companies have enough to sustain the dividend while retaining some for growth. This article explores the various pitfalls of traditional high-yield investing and proposes 3 high-yield stocks that offer a better total return potential.

DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (the “Company” or “FPI”) today announced that its Board of Directors has declared a one-time dividend of $1.15 per share of common stock and Class A Common OP Unit, payable in cash on January 8, 2025 to shareholders of record on December 23, 2024. The announcement comes at the end of a year that saw the Company sell farmland and related assets for consideration totaling approximately $308 million, generating a total gain for FPI of app.

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof.